• $675.00


Description :Rabbit Polyclonal Antibody

Species :

Tag :

Expression System:

Sequence :

Specificity :Recognizes the 43kDa CDK9 (PITALRE) protein

Cited Applications :ELISA, IHC, IP, WB
Ideal working dilutions for each application should be empirically determined by the investigator.

Cross Reactivity :Human, Rat and Mouse

Host Isotype / Clone# :Rabbit, Antiserum

Immunogen :The antibody was produced against synthesized peptides corresponding to the C-terminal and N-terminal domains of human CDK9 (PITALRE) protein.

Purification :Delipidation and defibrination

Stability :1yr at –20oC from date of shipment

Sample Data :Anti-CDK9 (1:1500) was used for Western blot analysis of 1) PC3 and 2) DU145 prostate cancer cells (50ug per lane). Bands at the expected MW of 55 and 42 Kda were detected.

Scientific Background :CDK9 is a member of the cyclin-dependent protein kinase (CDK) family. CDK9 is closely related to cdc28 and cdc2 and is an important regulator of the cell cycle (1). CDK9 is a component of the multiprotein complex TAK/P-TEFβ. CDK9 can modulate RNA polymerase II-directed transcription by phosphorylating the C-terminal domain of the largest subunit of RNA polymerase II. CDK9 forms a complex with and is regulated by its regulatory subunit cyclin T or cyclin K. CDK9 also interacts with the HIV-1 Tat protein which suggested a possible involvement of this protein in AIDS (2). 

References :
1. Yang, Z. et al: The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature, 2001; 414: 317-322. 

2. Bullrich, F. et al: Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27-Kip1, to regions involved in human cancer. Cancer Res. 1995; 55: 1199-1205.

Product Sheets (By Lot #) :


Research Areas :Cancer, Cell Cycle, Ser/Thr Kinases